Reports
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States
Americas
Future Market Insights, Inc.
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
MEA
Future Market Insights
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom
Asia Pacific
Future Market Insights
IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India
The global infertility drugs market size was valued at US$ 3,699.8 million in the year 2023 and is estimated to reach US$ 6,814.68 million by 2033. This market is projected to expand at a CAGR of 6.3% during the analysis period. The increased prevalence of infertility is expected to boost the demand for infertility drugs. Women and men are equally affected by infertility.
Female infertility can be caused by factors such as growing older, polycystic ovarian syndrome (PCOS), obesity, and miscarriages, while male infertility can be caused by factors such as erectile dysfunction, low sperm count, abnormal sperm, etc. Researchers at the BGU developed a new treatment that stimulates telomerase expression and re-elongates the telomeres to protect cells.
For treating infertility, market players are introducing novel medications. In the current instance, Oxolife is developing the first-in-class product candidate OXO-001, which is designed to enhance the binding of embryos to the inner lining of the uterus by increasing binding. Moreover, the United States-based biopharmaceutical company Ferring Pharmaceuticals recently launched its novel fertility treatment, Trisequens, for women.
Developing such products addresses a medical need that affects women around the world undergoing assisted reproduction because there is no substitute for improving the endometrium's conditions for embryo implantation.
Infertility medicines are expected to contribute positively to the market as well as the presence of a variety of products for treating these conditions. For example, In-vitro fertilization (IVF) treatments, which involve fertilizing an egg outside of the body, are becoming more commonplace and are expected to drive market growth.
Infertility problems are caused by hormonal imbalance, polycystic ovarian disease, and weight issues caused by sedentary lifestyles. Therefore, the market is likely to grow over the forecast period as sedentary lifestyles become increasingly popular. The market growth may likely be hindered by rigid regulatory frameworks for product approval and high-priced patented products.
Attributes | Details |
---|---|
Infertility Drugs Market Value (2023) | US$ 3,699.8 million |
Infertility Drugs Market Expected Value (2033) | US$ 6,814.68 million |
Infertility Drugs Market Projected CAGR (2023 to 2033) | 6.3% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global infertility drugs market expanded at 4.69% CAGR over the past 10 years. The market is expected to expand at a CAGR of close to 6.3% over the forthcoming decade. Due to the disruptions in the supply chain caused by the pandemic and the delay in delivering essential products needed to manufacture infertility drugs, the market for infertility drugs suffered. Additionally, fertility treatments were suspended or delayed across the globe during the pandemic, which also hampered market growth.
According to a study published by the National Library of Medicine in April 2021, ‘Suspension of fertility treatment during the pandemic: views, emotional reactions and psychological distress among women undergoing fertility treatment,’ fertility treatments were suspended during the initial phase of the pandemic. In such cases, it is evident that the market experienced slow growth during the pandemic.
Historical CAGR (2016 to 2022) | 4.69% |
---|---|
Historical Market Value (2022) | US$ 3,480 million |
Forecast CAGR | 6.3% |
Infertility Drugs Market:
Differentiating Aspects | Infertility Drugs Market |
---|---|
CAGR (2023 to 2033) | 6.3% |
Market Valuation in 2023 | US$ 3,699.8 million |
Projected Market Value in 2033 | US$ 6,814.68 million |
Growth Factors | Increased prevalence of lifestyle disorders. |
Opportunities | Increased adoption of various infertility procedures creates opportunities in the market. |
Key Trends | Improved treatments with fewer side effects through research and development. |
Infertility Treatment Market:
Differentiating Aspects | Infertility Treatment Market |
---|---|
CAGR (2023 to 2033) | 8% |
Market Valuation in 2023 | US$ 1.75 billion |
Projected Market Value in 2033 | US$ 3.78 billion |
Growth Factors | The growing popularity of stem cell-based therapies for the treatment of male infertility |
Opportunities | The growing popularity of advanced infertility treatments such as assisted reproductive technology creates opportunities. |
Key Trends | The growing popularity of stem cell-based therapies for the treatment of male infertility. |
Women’s Health Market:
Differentiating Aspects | Women’s Health Market |
---|---|
CAGR (2023 to 2033) | 5% |
Market Valuation in 2023 | US$ 40.1 billion |
Projected Market Value in 2033 | US$ 65.32 billion |
Growth Factors | Favorable policies initiated by governments worldwide to improve women’s health. |
Opportunities | Healthcare advances for women are accelerating, with implications for investors and stakeholders. |
Key Trends | Introduction of new products for women’s health, such as Relugolix and Orilissa. |
The World Health Organization states that infertility affects millions of people of reproductive age worldwide. Globally, 48 million couples and 186 million individuals suffer from infertility. An infertility condition can be caused by male, female, or a combination of male and female factors, or it may be unexplained.
Infertility rates have been associated with environmental and lifestyle factors such as smoking, excessive alcohol consumption, obesity, and exposure to environmental pollutants for both women and men. This continues to be the primary reason why infertility drugs are so popular.
Infertility treatments and In-vitro fertilization (IVF) procedures often involve fertility medications, which prepare the body for treatment and increase the chance of eggs being released from the ovaries.
The infertility treatment space may continue to advance. This is due to decreased fertility rates, an increase in fertility clinics globally, technological advances, and public-private partnerships. All these factors are expected to shape the infertility drugs market.
Governments around the world have taken several initiatives to provide insurance coverage for treatment for infertility patients. For instance, in the United Kingdom, the National Health Service (NHS) covers the cost of some infertility treatments. Also in Canada, provincial health insurance plans cover the cost of assisted reproductive technologies for eligible patients. Moreover, a recent initiative announced by the Ministry of Health, Labor, and Welfare (MHLW) in March 2022 increased patients’ access to treatment by lowering the cost by 70% and increasing prescription rates.
Infertility drugs market growth is hampered by the side effects shown by the drugs, such as headaches, upper respiratory tract infections, abnormal bleeding or spotting, vomiting, injection site pain, and Ovarian Hyperstimulation Syndrome (OHSS).
According to a study published in NCBI in 2016, up to 10% to 20% of women who consume infertility drugs can develop mild OHSS, which usually resolves on its own without treatment. Severe cases occur in about one percent of patients.
There is also a possibility that the increased adoption rate of effective alternatives to medications may negatively impact the growth of the market. According to a research article published in Reproductive Biomedicine, 2.5 million IVF procedures are performed every year globally. There is a high threat of substitutes during the forecast period since most European countries offer full funding for several IVF procedures.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
With a revenue share of 40.1% in 2023, the gonadotropins segment dominated the infertility drugs market and is expected to grow rapidly over the forecast period. Due to the high cost of products and their increased efficacy, some of the most commonly used gonadotropins to treat infertility patients include Gonal-F, Follitism, Menopur, and Bravelle.
The high efficacy associated with gonadotropins may attract a wider target population and expand revenue sources. Injections of chorionic gonadotropin without insurance, cost around US$ 397.83, while injections with insurance cost nearly US$ 304.76 per injection.
A phase 3 clinical trial was initiated by Bharat Serums and Vaccines Limited in March 2022. The trial was designed to evaluate the safety and effectiveness of Recombinant Human Follicle Stimulating Hormone 900 IU among women aged 20 to 39. In addition, QL1012 is currently being tested for ovarian stimulation in a phase 3 clinical trial conducted by Qilu Pharmaceutical Co., Ltd. As such, the launch of gonadotropins may continue to drive the industry at a high growth rate over the forecast period.
According to the market report, women dominated the market for infertility drugs in 2023 with a revenue share of 71.3%. This dominance was due in part to the wide availability of infertility drugs for women.
The women’s segment is expected to accelerate over the forecast period. This is due to the disease burden at reproductive age and the adoption of sedentary lifestyles, which interfere with ovulation.
An increasing prevalence of thyroid disorders and breast cancer, which require more radiation exposure, is the leading reason for infertility among women. This results in a dramatic decrease in fertility rates. Smoking and alcohol consumption are increasing, as are many illnesses like PCOS and uterine fibroids, causing an increase in demand.
According to an article, the prevalence of Polycystic Ovarian Syndrome (PCOS) in 2020 is estimated to range from 2.2% to 48.0% in many countries, including the United States, China, India, and Australia, among others. Therefore, the growth in prescriptions for drugs and the rising awareness of this condition among women is predicted to fuel the market.
According to the launch and rapid uptake of multiple infertility medicines, North America dominated the overall infertility drugs market by 35% in 2023. Research activities in the area of infertility are expected to create new opportunities for the region. Moreover, with women's hectic lifestyles and increased stress levels, North America is expected to dominate the world's infertility drug market during the projected period.
This dominance is primarily the result of rising menopausal illnesses, urinary infections, thyroid problems, endometriosis, and other conditions caused by these conditions. Over 5 million women of reproductive age are affected by PCOS, according to a study published by the Centers for Disease Control and Prevention (CDC).
Since the fertility rate in Canada was low in 2020, fewer babies were born in the country, according to Statistics Canada's report published in May 2022. As a result, such factors are expected to lead to an increase in the sale of infertility drugs in this region, thus boosting the market.
In the United States, oligozoospermia, varicocele, diabetes, and other diseases are on the rise, pushing the region's revenue share. As a result of improved healthcare infrastructure and an increased count of reproductive endocrinologists, the market for infertility drugs has expanded.
The United States' dominant position in the worldwide market is projected to be enhanced by government spending on women's healthcare awareness, an increase in geriatric women, and early product releases. The increasing rate of infertility and PCOS cases in the United States is driving the growth of the infertility drugs market.
This is due to a concentration of market players or manufacturers, acquisitions and partnerships among major players, and an increase in the number of cases of infertility and PCOS.
PCOS, one of the most common causes of female infertility in the United States, is estimated to affect around 6.0% to 12.0% of women of reproductive age annually, as reported by the Centers for Disease Control and Prevention (CDC) in March 2020. The market in the United States is likely to grow considerably because of such instances.
A market value of US$ 385.5 million is projected for the German market for infertility drugs by the year 2033. This results in Germany dominating the European Infertility Drugs Market in 2023. During the estimated period, Germany is projected to dominate the global market for infertility treatment drugs for women.
The ripeness rate of females in Germany was less than 2% in 2019, according to Eurostat. As a result of the high level of development in the healthcare industry, a high rate of infertility diagnosis and treatment, and a significant share of the market held by Germany in 2023.
Over the forecast period, India is projected to grow at a rate of 4.8%. Several key players in the market have participated in strategic initiatives to develop and commercialize effective infertility medicinal products to treat patients, which have contributed to the growth of the region.
According to the Ministry of Health, Labor, and Welfare (MHLW), 12 drugs were approved by the Ministry for the treatment of extra infertility in September 2022, including Novartis AG's Letrozole and Pfizer's Cabaser. This approval was expected to increase the market for novel drugs in India.
A generic form of Dydrogesterone tablets was developed and launched by Mankind Pharma in June 2022 in India to treat pregnancy-related complications. As a result of the launch, the infertility treatment market was expected to grow. This drug is equivalent to Abbott Duphaston tablets.
A new player in the fertility drugs market introduces novel products and forms alliances, collaborations, and partnerships. To accelerate innovation, digitization, and development in fertility treatment, CooperSurgical, a pioneer in women's healthcare solutions, established a multi-year strategic partnership with Virtus Health, a primary global provider of assisted reproductive services, in December 2021.
In June 2021, Hamilton Thorne Ltd. launched initiatives to help patients with fertility, including those who require egg, sperm, or embryo donations, emphasizing digitalization, cryogenics, and reproductive genetics. In the United States and Europe, GYNEMED GM501, a ready-to-use device designed for washing and handling human embryos and oocytes, has been approved by the United States FDA.
Several key players dominate the global infertility drugs market, which is moderately competitive. A competitive landscape analysis includes some international and local companies that hold the market share and are well known, such as Ferring Pharmaceuticals Inc., Merck KGaA, Bayer AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Theramex, and Novartis AG.
The strategy of mergers, acquisitions, investments, expansions of capacity, and plant turnarounds by major manufacturers, is further strengthening the market player presence and helping them in staying ahead of the competition.
Attribute | Details |
---|---|
Forecast Period | 2023 to 2033 |
Historical Data Available for | 2018 to 2023 |
Market Analysis | US$ million for Value and MT for Volume |
Key Regions Covered |
|
Key Countries Covered | United States, Canada, Brazil, Mexico, Chile, Peru, Germany, United Kingdom, Spain, Italy, France, Russia, Poland, China, India, Japan, Australia, New Zealand, GCC Countries, North Africa, and South Africa |
Key Segments Covered |
|
Key Companies Profiled |
|
Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
Customization & Pricing | Available upon Request |
The market is estimated to acquire US$ 3,699.8 million in 2023.
The increased prevalence of lifestyle disorders is the primary factor.
The United States accounts for the dominant market share.
Increased adoption of various infertility procedures creates opportunities.
A high level of development in the healthcare industry drives the market.
1. Executive Summary | Infertility Drugs Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033 5.3.1. Gonadotrophins 5.3.2. Aromatase Inhibitors 5.3.3. Selective Estrogen Receptor Modulators (SERMs) 5.3.4. Biguanides 5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033 6.3.1. Male 6.3.2. Female 6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033 7.3.1. Hospital Pharmacies 7.3.2. Retail Pharmacies 7.3.3. Online Pharmacies 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. South Asia 8.3.5. East Asia 8.3.6. Oceania 8.3.7. MEA 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. The USA 9.2.1.2. Canada 9.2.2. By Drug Class 9.2.3. By End User 9.2.4. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Class 9.3.3. By End User 9.3.4. By Distribution Channel 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Drug Class 10.2.3. By End User 10.2.4. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Class 10.3.3. By End User 10.3.4. By Distribution Channel 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United kingdom (UK) 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Drug Class 11.2.3. By End User 11.2.4. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Class 11.3.3. By End User 11.3.4. By Distribution Channel 11.4. Key Takeaways 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Malaysia 12.2.1.3. Singapore 12.2.1.4. Thailand 12.2.1.5. Rest of South Asia 12.2.2. By Drug Class 12.2.3. By End User 12.2.4. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Class 12.3.3. By End User 12.3.4. By Distribution Channel 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Drug Class 13.2.3. By End User 13.2.4. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Class 13.3.3. By End User 13.3.4. By Distribution Channel 13.4. Key Takeaways 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Drug Class 14.2.3. By End User 14.2.4. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Class 14.3.3. By End User 14.3.4. By Distribution Channel 14.4. Key Takeaways 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Drug Class 15.2.3. By End User 15.2.4. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Class 15.3.3. By End User 15.3.4. By Distribution Channel 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Drug Class 16.1.2.2. By End User 16.1.2.3. By Distribution Channel 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Drug Class 16.2.2.2. By End User 16.2.2.3. By Distribution Channel 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Drug Class 16.3.2.2. By End User 16.3.2.3. By Distribution Channel 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Drug Class 16.4.2.2. By End User 16.4.2.3. By Distribution Channel 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Drug Class 16.5.2.2. By End User 16.5.2.3. By Distribution Channel 16.6. UK 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Drug Class 16.6.2.2. By End User 16.6.2.3. By Distribution Channel 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Drug Class 16.7.2.2. By End User 16.7.2.3. By Distribution Channel 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Drug Class 16.8.2.2. By End User 16.8.2.3. By Distribution Channel 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Drug Class 16.9.2.2. By End User 16.9.2.3. By Distribution Channel 16.10. India 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Drug Class 16.10.2.2. By End User 16.10.2.3. By Distribution Channel 16.11. Malaysia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Drug Class 16.11.2.2. By End User 16.11.2.3. By Distribution Channel 16.12. Singapore 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Drug Class 16.12.2.2. By End User 16.12.2.3. By Distribution Channel 16.13. Thailand 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Drug Class 16.13.2.2. By End User 16.13.2.3. By Distribution Channel 16.14. China 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Drug Class 16.14.2.2. By End User 16.14.2.3. By Distribution Channel 16.15. Japan 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Drug Class 16.15.2.2. By End User 16.15.2.3. By Distribution Channel 16.16. South Korea 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Drug Class 16.16.2.2. By End User 16.16.2.3. By Distribution Channel 16.17. Australia 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Drug Class 16.17.2.2. By End User 16.17.2.3. By Distribution Channel 16.18. New Zealand 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Drug Class 16.18.2.2. By End User 16.18.2.3. By Distribution Channel 16.19. GCC Countries 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Drug Class 16.19.2.2. By End User 16.19.2.3. By Distribution Channel 16.20. South Africa 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Drug Class 16.20.2.2. By End User 16.20.2.3. By Distribution Channel 16.21. Israel 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Drug Class 16.21.2.2. By End User 16.21.2.3. By Distribution Channel 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Drug Class 17.3.3. By End User 17.3.4. By Distribution Channel 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Merck & Co., Inc. 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Ferring B.V. 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Organon Group of Companies 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Abbott 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Novartis AG 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Bayer AG 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Pfizer Inc. 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Mankind Pharma 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Teva Pharmaceutical Industries LTD. 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Sanofi 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 3: Global Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 4: Global Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033 Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 6: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 7: North America Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 8: North America Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033 Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 10: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 11: Latin America Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 12: Latin America Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033 Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 14: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 15: Europe Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 16: Europe Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033 Table 17: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 18: South Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 19: South Asia Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 20: South Asia Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033 Table 21: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 22: East Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 23: East Asia Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 24: East Asia Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033 Table 25: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 26: Oceania Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 27: Oceania Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 28: Oceania Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033 Table 29: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 30: MEA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 31: MEA Market Value (US$ Million) Forecast by End User, 2018 to 2033 Table 32: MEA Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by End User, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 8: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 9: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 10: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 11: Global Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 12: Global Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 13: Global Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 14: Global Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 17: Global Market Attractiveness by Drug Class, 2023 to 2033 Figure 18: Global Market Attractiveness by End User, 2023 to 2033 Figure 19: Global Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 20: Global Market Attractiveness by Region, 2023 to 2033 Figure 21: North America Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 22: North America Market Value (US$ Million) by End User, 2023 to 2033 Figure 23: North America Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 28: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 29: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 30: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 31: North America Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 32: North America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 33: North America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 34: North America Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 37: North America Market Attractiveness by Drug Class, 2023 to 2033 Figure 38: North America Market Attractiveness by End User, 2023 to 2033 Figure 39: North America Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 40: North America Market Attractiveness by Country, 2023 to 2033 Figure 41: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 42: Latin America Market Value (US$ Million) by End User, 2023 to 2033 Figure 43: Latin America Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 48: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 49: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 51: Latin America Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 52: Latin America Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 53: Latin America Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 54: Latin America Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 57: Latin America Market Attractiveness by Drug Class, 2023 to 2033 Figure 58: Latin America Market Attractiveness by End User, 2023 to 2033 Figure 59: Latin America Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 61: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 62: Europe Market Value (US$ Million) by End User, 2023 to 2033 Figure 63: Europe Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 68: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 69: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 70: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 71: Europe Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 72: Europe Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 73: Europe Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 74: Europe Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 77: Europe Market Attractiveness by Drug Class, 2023 to 2033 Figure 78: Europe Market Attractiveness by End User, 2023 to 2033 Figure 79: Europe Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 80: Europe Market Attractiveness by Country, 2023 to 2033 Figure 81: South Asia Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 82: South Asia Market Value (US$ Million) by End User, 2023 to 2033 Figure 83: South Asia Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 84: South Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 85: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 86: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 87: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 88: South Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 89: South Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 90: South Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 91: South Asia Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 92: South Asia Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 93: South Asia Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 94: South Asia Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 95: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 96: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 97: South Asia Market Attractiveness by Drug Class, 2023 to 2033 Figure 98: South Asia Market Attractiveness by End User, 2023 to 2033 Figure 99: South Asia Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 100: South Asia Market Attractiveness by Country, 2023 to 2033 Figure 101: East Asia Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 102: East Asia Market Value (US$ Million) by End User, 2023 to 2033 Figure 103: East Asia Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 104: East Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 105: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 108: East Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 109: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 111: East Asia Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 112: East Asia Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 113: East Asia Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 114: East Asia Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 115: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 116: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 117: East Asia Market Attractiveness by Drug Class, 2023 to 2033 Figure 118: East Asia Market Attractiveness by End User, 2023 to 2033 Figure 119: East Asia Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 120: East Asia Market Attractiveness by Country, 2023 to 2033 Figure 121: Oceania Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 122: Oceania Market Value (US$ Million) by End User, 2023 to 2033 Figure 123: Oceania Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 124: Oceania Market Value (US$ Million) by Country, 2023 to 2033 Figure 125: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 128: Oceania Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 129: Oceania Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 131: Oceania Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 132: Oceania Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 133: Oceania Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 134: Oceania Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 135: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 136: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 137: Oceania Market Attractiveness by Drug Class, 2023 to 2033 Figure 138: Oceania Market Attractiveness by End User, 2023 to 2033 Figure 139: Oceania Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 140: Oceania Market Attractiveness by Country, 2023 to 2033 Figure 141: MEA Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 142: MEA Market Value (US$ Million) by End User, 2023 to 2033 Figure 143: MEA Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 144: MEA Market Value (US$ Million) by Country, 2023 to 2033 Figure 145: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 148: MEA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 149: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 150: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 151: MEA Market Value (US$ Million) Analysis by End User, 2018 to 2033 Figure 152: MEA Market Value Share (%) and BPS Analysis by End User, 2023 to 2033 Figure 153: MEA Market Y-o-Y Growth (%) Projections by End User, 2023 to 2033 Figure 154: MEA Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 155: MEA Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 156: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 157: MEA Market Attractiveness by Drug Class, 2023 to 2033 Figure 158: MEA Market Attractiveness by End User, 2023 to 2033 Figure 159: MEA Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 160: MEA Market Attractiveness by Country, 2023 to 2033
Recommendations
Explore Healthcare Insights
View Reports